Disease activity in primary progressive multiple sclerosis: a systematic review and meta-analysis

Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis

(2023) Stephanie Meier et al.   JAMA Neurology

Current and Future Biomarkers in Multiple Sclerosis

(2022) Jennifer Yang et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Serum neurofilament light chain for individual prognostication of disease activity in people with multiple sclerosis: a retrospective modelling and validation study

(2022) Pascal Benkert et al.   LANCET NEUROLOGY

Prognostic Value of Serum Neurofilament Light Chain for Disease Activity and Worsening in Patients With Relapsing Multiple Sclerosis: Results From the Phase 3 ASCLEPIOS I and II Trials

(2022) Tjalf Ziemssen et al.   Frontiers in Immunology

Changes in prognosis of the Danish multiple sclerosis population over time

(2022) Melinda Magyari et al.   Multiple Sclerosis Journal

Disease-Modifying Treatments and Time to Loss of Ambulatory Function in Patients With Primary Progressive Multiple Sclerosis

(2022) Emilio Portaccio et al.   JAMA Neurology

The age at onset of relapsing-remitting multiple sclerosis has increased over the last five decades1

(2022) Lucía Romero-Pinel et al.   Multiple Sclerosis and Related Disorders

Serum neurofilament‐light and glial fibrillary acidic protein levels in hydroxychloroquine‐treated primary progressive multiple sclerosis

(2022) Carlos Camara‐Lemarroy et al.   EUROPEAN JOURNAL OF NEUROLOGY

Ageing and multiple sclerosis

(2022) Jennifer S Graves et al.   LANCET NEUROLOGY

Serum Neurofilament Light Chain and Glial Fibrillary Acidic Protein as Biomarkers in Primary Progressive Multiple Sclerosis and Hereditary Spastic Paraplegia Type 4

(2022) Christoph Kessler et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Diagnosis and Treatment of Multiple Sclerosis

(2021) Marisa P. McGinley et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Characterisation of MS phenotypes across the age span using a novel data set integrating 34 clinical trials (NO.MS cohort): Age is a key contributor to presentation

(2021) Frank Dahlke et al.   Multiple Sclerosis Journal

Immune Soluble Factors in the Cerebrospinal Fluid of Progressive Multiple Sclerosis Patients Segregate Into Two Groups

(2021) Gloria Donninelli et al.   Frontiers in Immunology

Clinical and radiological activity of secondary progressive multiple sclerosis in a population‐based cohort

(2021) Guillaume Mathey et al.   EUROPEAN JOURNAL OF NEUROLOGY

The PRISMA 2020 statement: an updated guideline for reporting systematic reviews

(2021) Matthew J Page et al.   BMJ-British Medical Journal

Short-term data on disease activity, cognition, mood, stigma and employment outcomes in a cohort of patients with primary progressive multiple sclerosis (UPPMS study)

(2021) Francisco Pérez-Miralles et al.   Multiple Sclerosis and Related Disorders

Association of Age With Contrast-Enhancing Lesions Across the Multiple Sclerosis Disease Spectrum

(2021) Marcus W. Koch et al.   NEUROLOGY

Difficulty in identification of patients with active secondary progressive multiple sclerosis by clinical classification tools

(2021) Svenja Klinsing et al.   EUROPEAN JOURNAL OF NEUROLOGY

The 2013 clinical course descriptors for multiple sclerosis

(2020) Fred D. Lublin et al.   NEUROLOGY

The apparently milder course of multiple sclerosis: changes in the diagnostic criteria, therapy and natural history

(2020) Per Soelberg Sorensen et al.   BRAIN

A randomized, placebo-controlled phase 2 trial of laquinimod in primary progressive multiple sclerosis

(2020) Gavin Giovannoni et al.   NEUROLOGY

Serum GFAP in multiple sclerosis: correlation with disease type and MRI markers of disease severity

(2020) Xavier Ayrignac et al.   Scientific Reports

Beneficial effects of autologous mesenchymal stem cell transplantation in active progressive multiple sclerosis

(2020) Panayiota Petrou et al.   BRAIN

Real‐world experience of ocrelizumab in multiple sclerosis in a Spanish population

(2020) Eva Fernandez‐Diaz et al.   Annals of Clinical and Translational Neurology

Pathogenic Mechanisms Associated With Different Clinical Courses of Multiple Sclerosis

(2019) Hans Lassmann   Frontiers in Immunology

Changes in the Risk of Reaching Multiple Sclerosis Disability Milestones In Recent Decades

(2019) Omid Beiki et al.   JAMA Neurology

Blood neurofilament light chain as a biomarker of MS disease activity and treatment response

(2019) Jens Kuhle et al.   NEUROLOGY

Treatment of multiple sclerosis with rituximab: A multicentric Italian–Swiss experience

(2019) Chiara Zecca et al.   Multiple Sclerosis Journal

Evaluating the efficacy and safety of ZytuxTM (Rituximab, AryoGen pharmed) in Iranian multiple sclerosis patients: An observational study

(2019) Abdorreza Naser Moghadasi et al.   Multiple Sclerosis and Related Disorders

Siponimod versus placebo in secondary progressive multiple sclerosis (EXPAND): a double-blind, randomised, phase 3 study

(2018) Ludwig Kappos et al.   LANCET

Progressive Forms of Multiple Sclerosis

(2018) Burcu Zeydan et al.   NEUROLOGIC CLINICS

Over three decades study populations in progressive multiple sclerosis have become older and more disabled, but have lower on-trial progression rates: A systematic review and meta-analysis of 43 randomised placebo-controlled trials

(2018) Richard S Nicholas et al.   Multiple Sclerosis Journal

Association of Inflammation and Disability Accrual in Patients With Progressive-Onset Multiple Sclerosis

(2018) Jordana Hughes et al.   JAMA Neurology

Anti-inflammatory disease-modifying treatment and disability progression in primary progressive multiple sclerosis: a cohort study

(2018) J. Lorscheider et al.   EUROPEAN JOURNAL OF NEUROLOGY

Ocrelizumab versus Placebo in Primary Progressive Multiple Sclerosis

(2017) Xavier Montalban et al.   NEW ENGLAND JOURNAL OF MEDICINE

Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial

(2016) Fred Lublin et al.   LANCET

A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study

(2016) Helga Westerlind et al.   Multiple Sclerosis Journal

Rituximab in multiple sclerosis

(2016) Jonatan Salzer et al.   NEUROLOGY

A significant decrease in diagnosis of primary progressive multiple sclerosis: A cohort study

(2016) Helga Westerlind et al.   Multiple Sclerosis Journal

Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis

(2015) Rikke Ratzer et al.   Multiple Sclerosis Journal

Evaluation of Study and Patient Characteristics of Clinical Studies in Primary Progressive Multiple Sclerosis: A Systematic Review

(2015) T. Ziemssen et al.   PLoS One

Monthly oral methylprednisolone pulse treatment in progressive multiple sclerosis

(2015) Rikke Ratzer et al.   Multiple Sclerosis Journal

TheVGAMPackage for Categorical Data Analysis

(2015) Thomas W. Yee   Journal of Statistical Software

Modelling the natural history of primary progressive multiple sclerosis

(2014) Katharine E Harding et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Relapses and disability accumulation in progressive multiple sclerosis

(2014) M. M. Paz Soldan et al.   NEUROLOGY

Natalizumab in progressive MS: Results of an open-label, phase 2A, proof-of-concept trial

(2014) J. Romme Christensen et al.   NEUROLOGY

Defining the clinical course of multiple sclerosis: The 2013 revisions

(2014) F. D. Lublin et al.   NEUROLOGY

Cortical lesion load associates with progression of disability in multiple sclerosis

(2012) M. Calabrese et al.   BRAIN

The changing face of multiple sclerosis clinical trial populations

(2011) Bernard M.J. Uitdehaag et al.   CURRENT MEDICAL RESEARCH AND OPINION

Lesion enhancement diminishes with time in primary progressive multiple sclerosis

(2010) Z. Khaleeli et al.   Multiple Sclerosis Journal

Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double-blind placebo-controlled multicenter trial

(2009) Kathleen Hawker et al.   ANNALS OF NEUROLOGY

Preferred Reporting Items for Systematic Reviews and Meta-Analyses: The PRISMA Statement

(2009) David Moher et al.   PLOS MEDICINE

Predicting progression in primary progressive multiple sclerosis: A 10-year multicenter study

(2008) Zhaleh Khaleeli et al.   ANNALS OF NEUROLOGY

Benefit with methylprednisolone in continuous pulsetherapy in progressive primary form of multiple sclerosis: study of 11 cases in 11 years

(2008) Edmar A.S. de Araújo et al.   ARQUIVOS DE NEURO-PSIQUIATRIA